Navigation Links
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix

LONDON, November 4, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:

Pfizer Inc.'s stock edged 0.80% higher, to close the day at $30.19. The stock recorded a trading volume of 21.60 million shares, below its three months average volume of 25.01 million shares. The company's shares oscillated between $29.86 and $30.20 during the session. Over the last three trading sessions and over the past one month, Pfizer Inc.'s shares have advanced 2.37% and 3.32%, respectively. However, the stock has fallen by 1.44% since the start of this year. The company's stock is trading above its 50-day and 200-day moving averages. Pfizer Inc. stock's 200-day moving average of $30.14 is above its 50-day moving average of $29.28. Additionally, the stock traded at a PE ratio of 16.15 and has a Relative Strength Index (RSI) of 63.98. Sign up and read the free notes on PFE at:

On Monday, shares in Merck and Co. Inc. recorded a trading volume of 10.15 million shares, close to its three months average volume of 10.11 million shares. The stock ended the day at $58.92, which was 1.69% above its previous day's closing of $57.94, and registered an intraday range of $57.57 and $58.93. Shares of the company traded at a PE ratio of 17.49. Merck and Co. Inc.'s stock has gained 4.84% in the previous three trading sessions, 3.73% in the last three months, and 17.72% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $58.66 and $57.15, respectively. Furthermore, shares of Merck and Co. Inc. have an RSI of 53.74. The complimentary notes on MRK can be downloaded as in PDF format at:

Sanofi's stock fell 0.99% to end Monday's session at $45.78. The stock recorded a trading volume of 4.74 million shares, much above its three months average volume of 1.68 million shares. The company's shares fluctuated between $45.41 and $45.78 during the session. Sanofi's shares have lost 14.64% since the beginning of 2014. Further, the stock has declined 16.38% in the last one month and 13.93% over the previous three months. The company's stock is trading below its 50-day and 200-day moving averages. The stock's 50-day moving average of $53.97 is above its 200-day moving average of $52.50. Additionally, the stock has an RSI of 28.75. Register for free on Investor-Edge and access the latest research on SNY at:

On Monday, shares in Shire PLC fluctuated between $195.00 and $198.77 before ending the session 1.66% lower at $196.49. The stock reported a trading volume of 1.01 million shares, lower than its three months average volume of 2.01 million shares. Shire PLC's shares have declined 25.21% in the last one month and 20.75% in the previous three months, while the stock has gained 39.07% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $236.28 and $198.33, respectively. Moreover, shares of Shire PLC have an RSI of 38.34. The complete research on SHPG is available for free at:

Zogenix Inc.'s stock finished Monday's session 7.09% higher at $1.36. A total of 1.99 million shares were traded, which was above its three months average volume of 1.74 million shares. The stock vacillated between $1.28 and $1.40 during the session. Over the previous three trading sessions and over the last three months, Zogenix Inc.'s shares have gained 3.82% and 5.43%, respectively. However, from the beginning of 2014, the stock has plummeted 60.47%. The company's shares are trading above their 50-day moving average. Moreover, the stock's 200-day moving average of $2.34 is greater than its 50-day moving average of $1.25. Zogenix Inc.'s stock has an RSI of 50.20. Free in depth research on ZGNX is available at:


At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.




1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at]

5. For any urgent concerns or inquiries, please contact us at compliance [at]

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
2. Reckitt Benckiser Pharmaceuticals Inc. Announces Appointment of Chief Financial Officer
3. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2015
4. PDL BioPharma to Announce Third Quarter 2014 Financial Results on November 10, 2014
5. ANI Pharmaceuticals Reports Record Third Quarter 2014 Financial Results and Year-To-Date Highlights
6. McCormack Pharma Announces a Breakthrough Discovery in the Mechanism of Clopidogrel Resistance
7. aTyr Pharma Appoints Fred Ramsdell, Ph.D., as Vice President, Immunology
8. Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation
9. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results
10. Isis Pharmaceuticals Earns $5 Million in Milestone Payment From GSK for Advancement of ISIS-GSK5 Rx
11. Kit Check Now Available to Canadian Hospital Pharmacies
Post Your Comments:
(Date:2/20/2020)... ... February 20, 2020 , ... PAINWeekEnd on March ... Arizona, will be a timely and relevant 2-day program providing busy clinicians and ... of chronic pain. , In 2020, paper prescriptions for certain painkillers have been ...
(Date:2/19/2020)... ... February 19, 2020 , ... Today, ... nursing facility rehospitalization rate are the lowest in the company’s history. , ... percent drop year over year. GHC’s skilled nursing facility (SNF) rehospitalization rate was ...
(Date:2/19/2020)... ... February 19, 2020 , ... ... has released a new SnapGene integration. This integration combines SnapGene’s ... View’ of supported DNA files, the molecular biology community has access to ...
Breaking Medicine Technology:
(Date:2/23/2020)... ... February 22, 2020 , ... One of the stars of ... is the host of the informational program “Behind The Scenes.” “Behind The Scenes” ... the country. A soon to be aired episode will interview industry professionals about ...
(Date:2/21/2020)... ... February 21, 2020 , ... Used for ... continues to garner traction as a viable replacement for invasive cosmetic surgery, such ... is predicted to remain the market leader for the expected robust growth of ...
(Date:2/20/2020)... ... ... R3 Stem Cell, the nation's leader in regenerative therapies and provider training, announced ... on military veterans in 2019. The veterans traveled from all over the US ... Training Course for doctors , providers of all kinds learn how to perform regenerative ...
(Date:2/19/2020)... ... 19, 2020 , ... The American College of Lifestyle Medicine ... Medicine Residency Curriculum (LMRC). The curriculum is the first comprehensive, applicable and flexible ... by resident involvement, the curriculum has included residents in every aspect of its ...
(Date:2/19/2020)... ... February 19, 2020 , ... ... will highlight its growing product portfolio for lower extremities at the American College ... B. Gonzalez Convention Center. The Trigon® Ti Stand-Alone Osteotomy Wedge Fixation System will ...
Breaking Medicine News(10 mins):